Pharmabiz2h
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples: San Diego Tuesday, January 14, 2025, 13:00 Hrs [IST] Illumina, ...
Pharmabiz7h
PDMA asks govt to create separate category for units below Rs. 10 crore & allow 3 years to implement revised Schedule M
The Punjab Drug Manufacturers Association (PDMA) has sought the Union ministry of health and family welfare to create a separate category for units below Rs. 10 crore turnover outside the erstwhile ...
Pharmabiz3d
NPPA recalculates ceiling price of azithromycin 250 mg following review order
The National Pharmaceutical Pricing Authority (NPPA) has released the revised calculation sheet for the ceiling price of azithromycin 250 mg tablet following a review order from the Department of ...
Pharmabiz6h
DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments
DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments: Our Bureau, Mumbai Tuesday, January 14, 2025, 09:00 Hrs ...
Pharmabiz3d
Astellas Pharma announces US FDA confirms Class 1 resubmission of the sNDA for Izervay for geographic atrophy
Astellas Pharma Inc. announced the US Food and Drug Administration (FDA) accepted the revised supplemental New Drug Application (sNDA) for Izervay (avacincaptad pegol intravitreal solution) for the ...
Pharmabiz5h
China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma
China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...
Pharmabiz2d
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Boehringer Ingelheim and Synaffix B.V. (Synaffix), a Lonza company focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs ...
Pharmabiz7h
HPMA demands three years’ time for full compliance with revised Schedule M
HPMA demands three years’ time for full compliance with revised Schedule M: Peethaambaran Kunnathoor, Chennai Tuesday, ...
Pharmabiz3d
US FDA accepts for review GSK’s Shingrix new prefilled syringe presentation
GSK plc, a global biopharma company, announced that the US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s ...
Pharmabiz2d
Seven research leaders awarded prestigious NIHR award
The NIHR has announced the latest outstanding researchers to become NIHR Research Professors. They will play a key role in undertaking professorial-level research that has a positive impact on the ...
Pharmabiz2d
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market
Gaelic Laboratories, a European CMO based in Ireland, has established a subsidiary in the UAE, enabling access to the Middle East market – both for Gaelic Laboratories and its marketing partners ...
Pharmabiz3d
IDMA plans extensive workshops on revised Schedule M to assist pharma MSMEs
With revision in extension of the deadline for implementing the revised Schedule M until December 31, 2025, the Indian Drug Manufacturers’ Association (IDMA) has announced plans to intensify its ...